Non-muscle-invasive bladder cancer : An overview of potential new treatment options
Shore, Neal D. (Carolina Urologic Research Center)
Palou, Juan (Institut d'Investigació Biomèdica Sant Pau)
Robert, Grégoire Y. (Department of Urology. CHU Bordeaux. University of Bordeaux)
Hutson, Thomas E. (Texas Oncology. Baylor Charles A. Sammons Cancer Center)
Cesari, Rossano (Pfizer Oncology)
Hariharan, Subramanian (Pfizer Oncology)
Rodríguez Faba, Óscar (Institut d'Investigació Biomèdica Sant Pau)
Briganti, Alberto (IRCCS Ospedale San Raffaele (Milà, Itàlia))
Steinberg, Gary D. (Perlmutter Cancer Center. an NCI-designated Comprehensive Cancer Center Goldstein Bladder Cancer Program. NYU Langone Health. NYU Urology Associates. New York University)
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	Aim: This review article summarizes the current clinical practice guidelines around disease definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer (NMIBC). Recently completed and ongoing clinical trials of novel and investigational therapies in Bacillus Calmette-Guérin (BCG)-naïve, BCG-recurrent, and BCG-unresponsive patient populations are also described, e. g. , those involving immune checkpoint inhibitors, targeted therapies, other chemotherapy regimens, vaccines, and viral- or bacterial-based treatments. Finally, a brief overview of enhanced cystoscopy and drug delivery systems for the diagnosis and treatment of NMIBC is provided. Background: A global shortage of access to BCG is affecting the management of BCG-naïve and BCG-recurrent/unresponsive NMIBC; hence, there is an urgent need to assist patients and urologists to enhance the treatment of this disease. Methods: Searches of ClinicalTrials. gov, PubMed, and Google Scholar were conducted. Published guidance and conference proceedings from major congresses were reviewed. Conclusion: Treatment strategies for NMIBC are generally consistent across guidelines. Several novel therapies have demonstrated promising antitumor activity in clinical trials, including in high-risk or BCG-unresponsive disease. The detection, diagnosis, surveillance, and treatment of NMIBC have also been improved through enhanced disease detection.
Note:	Altres ajuts: Pfizer.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	BCG ; Bladder cancer ; Immune checkpoint inhibitors ; Non-muscle-invasive ; Targeted therapy
Published in:	Urologic Oncology: Seminars and Original Investigations, Vol. 39 Núm. 10 (october 2021) , p. 642-663, ISSN 1873-2496

DOI: 10.1016/j.urolonc.2021.05.015
PMID: 34167873

22 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles